ERBB2 and breast cancer: When compared with single trastuzumab or pertuzumab treatments, the trastuzumab-pertuzumab combination induces a more complete suppression of HER2 signaling, thus resulting in synergistic anticancer effects against HER2 positive (HER2+) BC cells [6].